Sugentech Inc.

KOSDAQ:A253840 Stock Report

Market Cap: ₩85.9b

Sugentech Valuation

Is A253840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A253840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A253840 (₩5620) is trading above our estimate of fair value (₩879.34)

Significantly Below Fair Value: A253840 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A253840?

Key metric: As A253840 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A253840. This is calculated by dividing A253840's market cap by their current revenue.
What is A253840's PS Ratio?
PS Ratio12.1x
Sales₩7.08b
Market Cap₩85.93b

Price to Sales Ratio vs Peers

How does A253840's PS Ratio compare to its peers?

The above table shows the PS ratio for A253840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.7x
A214610 MiCo BioMed
7.1xn/a₩58.8b
A058110 MEKICS
2.7xn/a₩36.0b
A208370 SELVAS Healthcare
4.1xn/a₩116.5b
A228850 Rayence
0.8x6.9%₩102.8b
A253840 Sugentech
12.1xn/a₩85.9b

Price-To-Sales vs Peers: A253840 is expensive based on its Price-To-Sales Ratio (12.1x) compared to the peer average (3.7x).

Price to Sales Ratio vs Industry

How does A253840's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
A008490 Suheung
0.2x6.9%US$105.85m
A083550 KM
0.3xn/aUS$24.35m
No more companies available in this PS range
A253840 12.1xIndustry Avg. 2.1xNo. of Companies14PS0246810+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A253840 is expensive based on its Price-To-Sales Ratio (12.1x) compared to the KR Medical Equipment industry average (2.1x).

Price to Sales Ratio vs Fair Ratio

What is A253840's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A253840 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A253840's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Access Bio

₩188.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,570.00

7D

2.0%

1Y

-37.1%

Wonbiogen

₩43.5b

Develops and sells medical equipment in South Korea.

A307280

₩1,225.00

7D

-1.1%

1Y

-21.6%

Boditech Med

₩346.3b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩15,760.00

7D

-2.1%

1Y

-12.9%